ArticleBMC oral health2026
Incidence and clinicopathological profile of salivary gland neoplasms: a retrospective study from a tertiary centre.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSalivary gland neoplasms are a heterogeneous group of tumours with relatively low global incidence. The incidence of this neoplasm is poorly documented in the African population, and the pattern may differ from the rest of the world. This study aimed to determine the incidence and clinicopathological features of salivary gland neoplasms in an African population.
methodsThis was a retrospective study of histopathologically confirmed salivary gland neoplasms diagnosed at the University of Maiduguri Teaching Hospital, Nigeria, between January 2003 and December 2021. Data was obtained from histopathology records, request forms, and the departmental cancer registry. Information collected on demographics, tumour site, duration of symptoms and histopathological diagnosis. Non-residents and recurrent cases were excluded. Crude annual incidence rates were estimated using the Borno state population as the denominator.
resultsOne hundred and fifty-two salivary gland neoplasms were recorded in 148 patients. Four cases of recurrence were excluded. The mean age at diagnosis was 38 ± 16 years, with a male-to-female ratio of 1.2:1. Malignant neoplasms were more prevalent in males, with a ratio of 7.5:1. The age at diagnosis did not differ significantly between benign and malignant neoplasms (p = 0.212). The crude annual incidence rate was 0.15 per 100,000 population. Benign salivary gland neoplasms constituted 77.7% of cases. Pleomorphic adenoma was the most common neoplasm, accounting for 81.7% of benign neoplasms and 63.5% of all neoplasm while Warthin’s tumour was extremely rare (0.7%). Mucoepidermoid carcinoma was the second most common neoplasm overall (10.1%) and the most common malignant salivary gland neoplasm (45.5%). The major salivary glands were the most affected tumour location (69.5%), with the parotid gland being the most frequent site (45.3%). Tumour was extremely rare in the sublingual gland (0.7%).
conclusionsThis study revealed a low incidence of salivary gland neoplasms in this African population, with pleomorphic adenoma and mucoepidermoid carcinoma being the most common tumour types. The pattern of distribution, however, deviated from the reported 10:1:1 rule.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.